BPC-157 FDA Approval Status 2026: Clinical Trials

BPC-157 FDA Approval Status 2026: Clinical Trials. Is BPC-157 FDA approved in 2026? See the latest compounding review, FDA docket updates, and what researchers need to know. Key Takeaways BPC-157 is NOT FDA approved. No finished-drug approval, no active IND, and no FDA-registered human clinical trials as of April 2026. RFK Jr February 2026 announcement: HHS Secretary Robert F. Kennedy Jr. publicly stated that 14 of 19 previously Category 2 peptides — including BPC-157 — would return to Category 1 compounding status. July 23-24, 2026 FDA meeting: The Pharmacy Compounding Advisory Committee will formally review BPC-157 (free base and acetate salt), KPV, TB-500, and MOTS-c at the FDA White Oak Campus. Public docket FDA-2025-N-6895: Open for written comments through July 22, 2026, the day before the meeting convenes. Reclassification ≠ FDA approval. A Category 1 listing only means a compound can be legally prepared by 503A compounding pharmacies — it does not make BPC-157 an FDA-approved drug. Research-grade BPC-157 remains available for laboratory and investigational use only, outside the compounding and therapeutic pathways entirely. What Is BPC-157? BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — 15 amino acids long — derived from a protective protein naturally found in human gastric juice. Researchers have studied its effects on tissue repair, angiogenesis, and nitric oxide signaling in preclinical models for more than two decades. The peptide is typically sold in two chemical forms used in compounding and research: BPC-157 free base (also called the pure peptide) and BPC-157 acetate , a trifluoroacetate-free salt form. The FDA's 2026 advisory committee review treats each form as a distinct evaluation target. Property Detail Full Name Body Protection Compound 157 Amino Acids 15 (pentadecapeptide) Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Weight ~1,419 g/mol Forms reviewed by FDA Free base and acetate salt FDA Status Not approved Active IND applications None (as of April 2026) Compounding status Under reclassification review (July 23-24, 2026) Is BPC-157 FDA Approved in 2026? No. BPC-157 is not FDA approved. As of April 2026, the BPC-157 FDA approval status remains what it has been for the last two decades: no finished-drug approval, no active Investigational New Drug (IND) application, and no FDA-registered human clinical trials. The Drugs@FDA database contains no entry for BPC-157 in any indication, and ClinicalTrials.gov shows no ongoing human studies registered in the United States. That places BPC-157 in the same regulatory bucket as other unapproved research peptides like TB-500 (thymosin beta-4 fragment) and GHK-Cu . Researchers comparing repair peptides against growth-hormone-axis compounds should also read our Sermorelin vs BPC-157 breakdown. For the broader picture of which peptides ARE FDA approved, see our FDA Approved Peptides List 2026 . What has changed in 2026 is the compounding classification — the narrower regulatory question of whether 503A pharmacies can legally prepare BPC-157 prescriptions. That shift is driven by the RFK Jr announcement and the upcoming advisory committee meeting, covered below. The RFK Jr Announcement (February 27, 2026) On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly stated during a Joe Rogan podcast appearance — and reiterated in follow-up HHS communications — that the FDA would return 14 of 19 previously Category 2 peptides to Category 1 compounding status . BPC-157 was among the 14 peptides named. The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use). What the Categories Actually Mean Category Meaning 503A Compounding? Category 1 Bulk substance the FDA considers eligible for use in compounding pending final rulemaking Generally permitted Category 2 Bulk substance the FDA has significant safety, identity, or quality concerns about Not permitted during review Category 3 Substance requiring further evaluation Case-by-case Critically, Category 1 status is not FDA approval. It simply permits licensed 503A compounding pharmacies to prepare the substance in response to individual prescriptions while the agency completes formal rulemaking. A Category 1 BPC-157 is still an unapproved drug — just one that compounders can legally dispense under specific conditions. July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting The RFK Jr announcement set up a formal review. On July 23-24, 2026 , the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus (10903 New Hampshire Avenue, Silver Spring, MD 20993) to evaluate whether several peptides should be added to the Section 503A bulk drug substances list. The peptides specifically scheduled for review at the 2026 meeting include: BPC-157 free base BPC-157 acetate KPV (lysine-proline-valine tripeptide) TB-500 (thymosin beta-4 fragment) MOTS-c (mitochondrial-derived peptide) The committee will vote on whether each listed substance meets the statutory criteria under Section 503A(b)(1)(A)(i)(III) of the Federal Food, Drug, and Cosmetic Act for inclusion on the bulk drug substances list used in compounding. Public Docket FDA-2025-N-6895 Written comments on BPC-157 and the other peptides under review can be submitted to public docket FDA-2025-N-6895 . The deadline for written comments is July 22, 2026 — the day before the meeting convenes. Oral presentations during the open public hearing require a separate request submitted to the FDA in advance. The advisory committee's recommendation is not binding, but historically the FDA adopts PCAC vote outcomes in its final 503A bulk substance determinations. A favorable PCAC vote would pave the way for formal Category 1 rulemaking; an unfavorable vote would likely maintain Category 2 status regardless of the RFK Jr statement. What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy. It does not create a branded finished drug, it does not trigger insurance coverage, and it does not retroactively validate marketing claims made about the compound. Clinical Trial Landscape The BPC-157 clinical trials status is a critical piece of the 2026 picture. Despite more than 500 published preclinical studies (primarily animal and cell-culture models from Sikiric and colleagues at the University of Zagreb), there have been essentially no registered human clinical trials for BPC-157 in the United States. ClinicalTrials.gov searches return no active Phase 1, 2, or 3 trials. No pharmaceutical company has filed an IND application disclosed in the public record. This is the central regulatory problem that full FDA approval would need to solve — and it is the reason PCAC reviews for peptides like BPC-157 often hinge on available safety data rather than efficacy evidence from controlled human studies. BPC-157 vs Other Peptides Under Review The July 2026 advisory committee meeting is reviewing a cluster of peptides together. Here's how they compare: Peptide Primary research area FDA status Advisory committee review BPC-157 Tissue repair, angiogenesis Not approved Yes (free base + acetate) TB-500 Actin regulation, cell migration Not approved Yes MOTS-c Mitochondrial metabolism Not approved Yes KPV Anti-inflammatory Not approved Yes GHK-Cu Copper-peptide skin/healing Not approved Not on 2026 agenda For a deeper comparison of BPC-157 and its most-researched counterpart, see our BPC-157 vs TB-500 research comparison . Research-Grade BPC-157 vs Compounded BPC-157 There are two distinct supply channels for BPC-157, and the 2026 FDA activity only affects one of them: Research/laboratory grade: Sold by peptide research suppliers with third-party certificates of analysis (COA). Legal for laboratory and investigational use only. Not affected by the 503A compounding review. Not intended for human consumption. Compounded prescription: Prepared by a licensed 503A compounding pharmacy pursuant to a valid prescription from a licensed prescriber. This channel is the one directly affected by the Category 1/Category 2 decision. For researchers working in preclinical and laboratory contexts, the July 2026 decision does not change availability of research-grade material. It changes what happens downstream in the clinical compounding ecosystem. Frequently Asked Questions Is BPC-157 FDA approved in 2026? No. BPC-157 is not FDA approved for any therapeutic indication as of April 2026. The RFK Jr announcement and the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting concern 503A compounding classification, not finished-drug approval. There are no active IND applications or FDA-registered human clinical trials for BPC-157. What did RFK Jr announce about BPC-157? On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly stated that 14 of 19 previously Category 2 peptides — BPC-157 among them — would return to Category 1 compounding status. That announcement precedes the formal July 2026 Pharmacy Compounding Advisory Committee vote but does not replace it. Final classification depends on the committee's recommendation and the FDA's subsequent rulemaking. When will the FDA decide on BPC-157 compounding status? The Pharmacy Compounding Advisory Committee will meet on July 23-24, 2026 to review BPC-157 (both free base and acetate forms), KPV, TB-500, and MOTS-c. Public written comments can be submitted to docket FDA-2025-N-6895 through July 22, 2026. Final FDA rulemaking typically follows the committee vote by several months to a year. Does Category 1 status mean BPC-157 is FDA approved? No. Category 1 status only means a substance is eligible for use by 503A compounding pharmacies pending final FDA rulemaking. It is not FDA approval as a finished drug product. BPC-157 would still require a full New Drug Application (NDA) supported by adequate human clinical trials to achieve formal FDA approval. What is the BPC-157 TB-500 FDA approval status 2026? Both remain unapproved. The BPC-157 TB-500 FDA approval status 2026 is identical at the approval level — neither compound has FDA approval, active INDs, or registered human clinical trials. Both are on the July 2026 Pharmacy Compounding Advisory Committee agenda for 503A compounding review, which is a separate regulatory question from approval. For the parallel review of TB-500 specifically, see our TB-500 FDA approval status 2026 breakdown. Can I legally buy BPC-157 in 2026? Research-grade BPC-157 is legal to purchase for laboratory and investigational research in the United States. It is not a DEA-scheduled controlled substance. It is not legal to sell as a dietary supplement, and it is not approved for human consumption. Compounded BPC-157 from a 503A pharmacy requires a valid prescription from a licensed prescriber and depends on the compounding classification outcome. Is BPC-157 banned by WADA? As of April 2026, BPC-157 is not explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List by name, though WADA's catch-all S0 category (non-approved substances) captures any compound without regulatory approval for human therapeutic use. This contrasts with TB-500, which is explicitly WADA-prohibited under S2. Conclusion The BPC-157 FDA approval status 2026 is unambiguous at the approval level: BPC-157 is not FDA approved, has no active IND, and has no registered human clinical trials. What's new in 2026 is the compounding classification review — driven by the February 27, 2026 RFK Jr announcement and formalized at the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. If the committee votes favorably and the FDA adopts the recommendation, BPC-157 could return to Category 1 status, allowing 503A compounding pharmacies to prepare it against valid prescriptions. That is a meaningful shift for the clinical compounding ecosystem — but it is not the same as FDA approval of a finished drug product. For researchers, the laboratory-grade supply channel remains unchanged. For a direct comparison with the parallel peptide under review, see our TB-500 FDA approval status 2026 article. For the broader picture of which peptides already have FDA approval, see our FDA Approved Peptides List 2026 . Reconstitution math: Use our free Peptide Calculator to determine concentration, syringe units, and doses per vial for your research protocols. References U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee — July 23-24, 2026 Meeting. fda.gov U.S. Food and Drug Administration. FDA-2025-N-6895 Public Docket — 503A Compounding Bulk Drug Substances List Nominations (comments due July 22, 2026). regulations.gov U.S. Food and Drug Administration. Human Drug Compounding — Section 503A of the FD&C Act. fda.gov Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des . 2011;17(16):1612-32. PubMed Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol . 2011;110(3):774-80. PubMed Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des . 2018;24(18):1972-1989. PubMed Drugs@FDA Database — search for "BPC-157" (returns no results confirming unapproved status). accessdata.fda.gov ClinicalTrials.gov. BPC-157 clinical trial registry search (no active US Phase 1-3 trials). clinicaltrials.gov PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.